Literature DB >> 20181709

Antiretroviral therapy in the clinic.

Athe M N Tsibris1, Martin S Hirsch.   

Abstract

Antiretroviral therapy in the developed world has resulted in substantial reductions in HIV-associated morbidity and mortality, changing an HIV diagnosis from a likely death sentence into a manageable chronic infection (F. J. Palella, Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg, N. Engl. J. Med. 338:853-860, 1998). Several million years of life have been saved by effective anti-HIV treatment, although these successes should not obscure the magnitude of the ongoing worldwide HIV epidemic (R. P. Walensky, A. D. Paltiel, E. Losina, L. M. Mercincavage, B. R. Schackman, P. E. Sax, M. C. Weinstein, and K. A. Freedberg, J. Infect. Dis. 194:11-19, 2006). Readers of the Journal of Virology are doubtless aware of the fundamental advances in retrovirology that have made possible the development of potent inhibitors of HIV replication. In this review, we focus on the issues surrounding how these drugs and drug regimens are actually used in clinical settings. Their proper use requires detailed knowledge of the natural history of HIV infection, the pharmacology of the individual drugs, the complexities of drug-drug interactions, and the use of sophisticated molecular tests for monitoring of viral load, immunologic response, and drug resistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20181709      PMCID: PMC2876604          DOI: 10.1128/JVI.02524-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  69 in total

1.  Tenofovir and changes in renal function.

Authors:  Samir K Gupta
Journal:  Clin Infect Dis       Date:  2005-08-15       Impact factor: 9.079

2.  HIV antiretroviral treatment: early versus later.

Authors:  Josephine Mauskopf; Mari Kitahata; Teresa Kauf; Anke Richter; Jerry Tolson
Journal:  J Acquir Immune Defic Syndr       Date:  2005-08-15       Impact factor: 3.731

3.  Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART.

Authors:  Richard E Nettles; Tara L Kieffer; Patty Kwon; Daphne Monie; Yefei Han; Teresa Parsons; Joseph Cofrancesco; Joel E Gallant; Thomas C Quinn; Brooks Jackson; Charles Flexner; Kathryn Carson; Stuart Ray; Deborah Persaud; Robert F Siliciano
Journal:  JAMA       Date:  2005-02-16       Impact factor: 56.272

Review 4.  Integrase inhibitors to treat HIV/AIDS.

Authors:  Yves Pommier; Allison A Johnson; Christophe Marchand
Journal:  Nat Rev Drug Discov       Date:  2005-03       Impact factor: 84.694

5.  Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population.

Authors:  D R Bangsberg; F M Hecht; E D Charlebois; A R Zolopa; M Holodniy; L Sheiner; J D Bamberger; M A Chesney; A Moss
Journal:  AIDS       Date:  2000-03-10       Impact factor: 4.177

6.  Adherence to protease inhibitor therapy and outcomes in patients with HIV infection.

Authors:  D L Paterson; S Swindells; J Mohr; M Brester; E N Vergis; C Squier; M M Wagener; N Singh
Journal:  Ann Intern Med       Date:  2000-07-04       Impact factor: 25.391

7.  Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects.

Authors:  J Q Purnell; A Zambon; R H Knopp; D J Pizzuti; R Achari; J M Leonard; C Locke; J D Brunzell
Journal:  AIDS       Date:  2000-01-07       Impact factor: 4.177

8.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators.

Authors:  F J Palella; K M Delaney; A C Moorman; M O Loveless; J Fuhrer; G A Satten; D J Aschman; S D Holmberg
Journal:  N Engl J Med       Date:  1998-03-26       Impact factor: 91.245

9.  Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study.

Authors:  S Tsiodras; C Mantzoros; S Hammer; M Samore
Journal:  Arch Intern Med       Date:  2000-07-10

10.  The effects of HIV protease inhibitors atazanavir and lopinavir/ritonavir on insulin sensitivity in HIV-seronegative healthy adults.

Authors:  Mustafa A Noor; Rex A Parker; Edward O'Mara; Dennis M Grasela; Alexander Currie; Sally L Hodder; Fred T Fiedorek; David W Haas
Journal:  AIDS       Date:  2004-11-05       Impact factor: 4.177

View more
  17 in total

1.  Understanding the molecular mechanism of sequence dependent tenofovir removal by HIV-1 reverse transcriptase: differences in primer binding site versus polypurine tract.

Authors:  Pinar Iyidogan; Karen S Anderson
Journal:  Antiviral Res       Date:  2012-06-01       Impact factor: 5.970

2.  Identification of mechanistically distinct inhibitors of HIV-1 reverse transcriptase through fragment screening.

Authors:  Jennifer La; Catherine F Latham; Ricky N Tinetti; Adam Johnson; David Tyssen; Kelly D Huber; Nicolas Sluis-Cremer; Jamie S Simpson; Stephen J Headey; David K Chalmers; Gilda Tachedjian
Journal:  Proc Natl Acad Sci U S A       Date:  2015-05-18       Impact factor: 11.205

3.  Use of biological knowledge to inform the analysis of gene-gene interactions involved in modulating virologic failure with efavirenz-containing treatment regimens in ART-naïve ACTG clinical trials participants.

Authors:  Benjamin J Grady; Eric S Torstenson; Paul J McLaren; Paul I W DE Bakker; David W Haas; Gregory K Robbins; Roy M Gulick; Richard Haubrich; Heather Ribaudo; Marylyn D Ritchie
Journal:  Pac Symp Biocomput       Date:  2011

4.  Identification and characterization of persistent intracellular human immunodeficiency virus type 1 integrase strand transfer inhibitor activity.

Authors:  Yasuhiro Koh; Hillel Haim; Alan Engelman
Journal:  Antimicrob Agents Chemother       Date:  2010-11-08       Impact factor: 5.191

5.  Identification of highly conserved residues involved in inhibition of HIV-1 RNase H function by Diketo acid derivatives.

Authors:  Angela Corona; Francesco Saverio Di Leva; Sylvain Thierry; Luca Pescatori; Giuliana Cuzzucoli Crucitti; Frederic Subra; Olivier Delelis; Francesca Esposito; Giuseppe Rigogliuso; Roberta Costi; Sandro Cosconati; Ettore Novellino; Roberto Di Santo; Enzo Tramontano
Journal:  Antimicrob Agents Chemother       Date:  2014-08-04       Impact factor: 5.191

6.  Restriction fragment mass polymorphism (RFMP) analysis based on MALDI-TOF mass spectrometry for detecting antiretroviral resistance in HIV-1 infected patients.

Authors:  J-H Lee; A Hachiya; S-K Shin; J Lee; H Gatanaga; S Oka; K A Kirby; Y T Ong; S G Sarafianos; W R Folk; W Yoo; S P Hong; S-O Kim
Journal:  Clin Microbiol Infect       Date:  2013-03-11       Impact factor: 8.067

7.  Microbial Translocation and B Cell Dysfunction in Human Immunodeficiency Virus Disease.

Authors:  Wei Jiang
Journal:  Am J Immunol       Date:  2012

8.  Human endogenous retrovirus expression is inversely associated with chronic immune activation in HIV-1 infection.

Authors:  Christopher E Ormsby; Devi Sengupta; Ravi Tandon; Steven G Deeks; Jeffrey N Martin; R Brad Jones; Mario A Ostrowski; Keith E Garrison; Joel A Vázquez-Pérez; Gustavo Reyes-Terán; Douglas F Nixon
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

Review 9.  Clinical management of HIV drug resistance.

Authors:  Karoll J Cortez; Frank Maldarelli
Journal:  Viruses       Date:  2011-04-14       Impact factor: 5.048

Review 10.  Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.

Authors:  Christopher J De Feo; Carol D Weiss
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.